# Nikolay Savchuk > Nikolay Savchuk is a seed investor at Teal Ventures Fund I backing Biotechnology and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Teal Ventures Fund I](https://shizune.co/investors/profile/teal-ventures-fund-i) - Location: San Diego, United States - Total investments: 4 - Last investment: Sep 2025 - Lead investor: 25% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/nikolay-savchuk-078a27 Nikolay Savchuk is a seed investor at Teal Ventures Fund I in San Diego focused on Biotechnology and Medical. Nikolay Savchuk Ph.D. is a serial entrepreneur and experienced international investor in the healthcare and IT industries for 23 years. Dr. Savchuk is the co-founder and Managing Partner at San Diego-based Torrey Pines Investment LLC, Chairman of the Board of ChemDiv Inc and Viriom Inc.The scope of main interest of Dr. Savchuk is life sciencesincluding rational drug design, AI and expert systems design control science, drug discovery and digital health technologies. Dr. Savchuk led and continues to manage successful investments in pharmaceutical and drug development companies. Dr. Savchuk obtained the MS degree in physics in 1994 and Ph.D. in applied mathematics in 2000 from Moscow Institute of Physics and Technology. He is an inventor and author of over 100 patents and research publications. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 3 | 75% | | Medical | 1 | 25% | | Real Time | 1 | 25% | | Health Care | 1 | 25% | | Life Science | 1 | 25% | 7 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Seed | 1 | 25% | | Series A | 1 | 25% | | Series B | 1 | 25% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 2 | 50% | | Portugal | 1 | 25% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Mondego Bio | Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile. | | Series A | Sep 18, 2025 | | | Avelas Biosciences | At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $7.4M | Series B | Sep 10, 2014 | | | Avelas Biosciences | At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $6.8M | Series B | Jan 09, 2014 | | | Chromis Therapeutics | Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company, focused on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. The company is seeking investment to advance its novel cccDNA inhibitor (CHR101), viral entry and viral capsidassembly inhibitor lead candidates for the treatment of chronic HBV. CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. CHR101's activity is supported by a robust discovery preclinical data package. | $3M | Seed | | | 4 of 4 investments shown. ## Co-investors - [Biovance Capital](https://shizune.co/investors/profile/biovance-capital) — VC Fund, 3 deals together - [Avalon Ventures](https://shizune.co/investors/profile/avalon-ventures) — VC Fund, 2 deals together - [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 1 deal together - [WuXi AppTec](https://shizune.co/investors/profile/wuxi-apptec) — VC Fund, 1 deal together - [WuXi Healthcare Ventures](https://shizune.co/investors/profile/wuxi-healthcare-ventures) — VC Fund, 1 deal together ## About Teal Ventures Fund I VC Fund 1 contacts available at Teal Ventures Fund I. | Name | Title | Profile | | --- | --- | --- | | Nikolay Savchuk | Managing General Partner | https://shizune.co/investors/profile/nikolay-savchuk-ph-d | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund ## FAQ ### What does Nikolay Savchuk invest in? Nikolay Savchuk invests primarily in Biotechnology, Medical and Real Time startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Nikolay Savchuk last invest? The most recent investment recorded for Nikolay Savchuk closed in Sep 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co